Ferric Derisomaltose
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ferric Derisomaltose
- Ferric derisomaltose: From Iron Replacement to Severe Nonproliferative Diabetic Retinopathy
Ferric derisomaltose: From Iron Replacement to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Ferric derisomaltose is an intravenous iron replacement product, marketed in Singapore as Monofer. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but no clinical trials and no publications currently support this direction, so the prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (the product is generally known as an intravenous iron replacement) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ferric derisomaltose is an intravenous iron product used to replace iron in iron deficiency anaemia. Its efficacy in that setting is established, but no mechanism has been identified that would make it applicable to severe nonproliferative diabetic retinopathy.
Iron-related oxidative stress is plausibly relevant to retinal disease, but this is speculative. Excess iron is more often linked to retinal oxidative damage than to treatment of it. The high score most likely reflects proximity in the knowledge graph rather than biological rationale. Intravenous iron has no known therapeutic role in diabetic retinopathy.
The other predictions are also unsupported and have no trials or literature. They include diabetic retinopathy (96.73%), esotropia (95.61%), non-syndromic esophageal malformation (94.62%), haemorrhagic disease of the newborn (92.34%), dermatitis (91.44%), acrodermatitis chronica atrophicans (90.60%), filariasis (90.25%), neonatal dermatomyositis (89.81%) and familial hydroa vacciniforme (89.18%). All are rated L5 with a recommendation of Hold. For several of them (for example the newborn conditions), intravenous iron would also raise safety concerns.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15855P | MONOFER® Solution for Injection or Infusion 100 mg/ml | Injection, solution | Not stated in the licence record |
Safety Considerations
- Drug Interactions (5 interactions recorded in the interaction database):
- Major: Dimercaprol
- Moderate: Iron, ferrous fumarate, ferrous gluconate, chloramphenicol
For other safety information, such as warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no clinical trials, no literature and no plausible mechanistic link. Iron excess is, if anything, associated with retinal oxidative damage. Evidence is at the lowest level (L5).
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking iron replacement to diabetic retinopathy
- Preclinical or observational evidence supporting a benefit in retinal disease
- The Singapore package insert, to confirm the approved indication, warnings and contraindications
- A review of the route of administration and whether intravenous iron is appropriate for an ocular indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.